{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:15:18Z","timestamp":1787022918316,"version":"build-2736575974"},"reference-count":86,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Cancer predisposes to venous thromboembolic complications, especially at the moment of diagnosis, and anticoagulation may be less effective. Additionally, some cancers, especially in the gastrointestinal tract or the genitourinary system, may be associated with an extremely high risk of bleeding. Anticoagulant treatment in venous thromboembolism associated with cancer is characterised by significant differences compared with the general cardiology population. It is necessary to choose the appropriate anticoagulation, either a new non-vitamin K antagonist oral anticoagulant or low-molecular-weight heparin. The efficacy and safety are determined by characteristics of the cancer and anticancer therapy. The duration of anticoagulation determines not only the choice of anticoagulant, but also the dose. There is some evidence to justify the reduction of anticoagulant dosage after 6 months of treatment. In active cancer, it is worth continuing anticoagulation indefinitely, but this does not necessarily mean for the rest of a patient\u2019s life. It is important to repeat an assessment when the risk of bleeding outweighs the benefits.<\/jats:p>","DOI":"10.15420\/ecr.2025.46","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:53:10Z","timestamp":1773157990000},"source":"Crossref","is-referenced-by-count":2,"title":["Venous Thromboembolism Management and Anticoagulation Opportunities in Cancer Patients"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-1943","authenticated-orcid":false,"given":"Sebastian","family":"Szmit","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04qcjsm24","id-type":"ROR","asserted-by":"publisher"}],"name":"The Maria Sklodowska-Curie National Research Institute of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Krzakowski","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04qcjsm24","id-type":"ROR","asserted-by":"publisher"}],"name":"The Maria Sklodowska-Curie National Research Institute of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz M","family":"Kowalski","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04qcjsm24","id-type":"ROR","asserted-by":"publisher"}],"name":"The Maria Sklodowska-Curie National Research Institute of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Zaborowska-Szmit","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04qcjsm24","id-type":"ROR","asserted-by":"publisher"}],"name":"The Maria Sklodowska-Curie National Research Institute of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Rak J, Yu JL, Luyendyk J, Mackman N. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006;66:10643\u20136. https:\/\/doi.org\/10.1158\/0008-5472.can-06-2350; pmid:\u00a017108099.","DOI":"10.1158\/0008-5472.CAN-06-2350"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"moik f, Ay C. Hemostasis and cancer: impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer. J Thromb Haemost 2022;20:2733\u201345. https:\/\/doi.org\/10.1111\/jth.15880; PMID:\u00a036106749.","DOI":"10.1111\/jth.15880"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Douketis JD, Gu C, Piccioli A, et al. The long-term risk of cancer in patients with a first episode of venous thromboembolism. J Thromb Haemost 2009;7:546\u201351. https:\/\/doi.org\/10.1111\/j.1538-7836.2008.03268.x; PMID:\u00a019143921.","DOI":"10.1111\/j.1538-7836.2008.03268.x"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"H\u00e4gg L, Ehrs F, Lind M, Johansson M. Cancer incidence and mortality after a first-ever venous thrombosis: a cohort study in northern Sweden. Thromb J 2024;22:77. https:\/\/doi.org\/10.1186\/s12959-024-00646-z; PMID:\u00a039169417.","DOI":"10.1186\/s12959-024-00646-z"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"van de Munckhof A, Verhoeven JI, Vaartjes ICH, et al. Incidence of newly diagnosed cancer after cerebral venous thrombosis. JAMA Netw Open 2025;8:e2458801. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.58801; PMID:\u00a039928336.","DOI":"10.1001\/jamanetworkopen.2024.58801"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Giustozzi M, Curcio A, Weijs B, et al. Variation in the association between antineoplastic therapies and venous thromboembolism in patients with active cancer. Thromb Haemost 2020;120:847\u201356. https:\/\/doi.org\/10.1055\/s-0040-1709527; PMID:\u00a032369855.","DOI":"10.1055\/s-0040-1709527"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"K\u0119pski J, Szmit S, Lech-Mara\u0144da E. Time relationship between the occurrence of a thromboembolic event and the diagnosis of hematological malignancies. Cancers (Basel) 2024;16:3196. https:\/\/doi.org\/10.3390\/cancers16183196; PMID:\u00a039335167.","DOI":"10.3390\/cancers16183196"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ahlbrecht J, Dickmann B, Ay C, et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2012;30:3870\u20135. https:\/\/doi.org\/10.1200\/JCO.2011.40.1810; PMID:\u00a023008313.","DOI":"10.1200\/JCO.2011.40.1810"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Dickmann B,\u00a0Ahlbrecht J, Ay C, et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 2013;98:1309\u201314. https:\/\/doi.org\/10.3324\/haematol.2012.073338; PMID:\u00a023585523.","DOI":"10.3324\/haematol.2012.073338"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"K\u00f6nigsbr\u00fcgge O, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb Res 2014;133(Suppl 2):S39\u201343. https:\/\/doi.org\/10.1016\/S0049-3848(14)50007-2; PMID:\u00a024862144.","DOI":"10.1016\/S0049-3848(14)50007-2"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Grover SP, Hisada YM, Kasthuri RS, et al. Cancer therapy-associated thrombosis. Arterioscler Thromb Vasc Biol 2021;41:1291\u2013305. https:\/\/doi.org\/10.1161\/ATVBAHA.120.314378; PMID:\u00a033567864.","DOI":"10.1161\/ATVBAHA.120.314378"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021;137:1959\u201369. https:\/\/doi.org\/10.1182\/blood.2020007338; PMID:\u00a033171494.","DOI":"10.1182\/blood.2020007338"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen HT, Pedersen L, van Es N, et al. Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study. Lancet Reg Health Eur 2023;34:100739. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100739; PMID:\u00a037809052.","DOI":"10.1016\/j.lanepe.2023.100739"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Moik F, Chan WE, Wiedemann S, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 2021;137:1669\u201378. https:\/\/doi.org\/10.1182\/blood.2020007878; PMID:\u00a033067632.","DOI":"10.1182\/blood.2020007878"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Su Y, Huo M, Hua L, et al. Association of venous thromboembolism and early mortality in patients with newly diagnosed metastatic non-small cell lung cancer. Cancer Manag Res 2021;13:4031\u201340. https:\/\/doi.org\/10.2147\/CMAR.S301088; PMID:\u00a034040443.","DOI":"10.2147\/CMAR.S301088"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Zaborowska-Szmit M, Szmit S, Olszyna-Serementa M, et al. Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancer. Cardiooncology 2024;10:79. https:\/\/doi.org\/10.1186\/s40959-024-00281-7; PMID:\u00a039522050.","DOI":"10.1186\/s40959-024-00281-7"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Khorana AA, DeSancho MT, Liebman H, et al. Prediction and prevention of cancer-associated thromboembolism. Oncologist 2021;26:e2\u20137. https:\/\/doi.org\/10.1002\/onco.13569; PMID:\u00a033274815.","DOI":"10.1002\/onco.13569"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Moik F, Ay C, Pabinger I. Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. Thromb Res 2020;191(Suppl 1):S3\u201311. https:\/\/doi.org\/10.1016\/S0049-3848(20)30389-3; PMID:\u00a032736775.","DOI":"10.1016\/S0049-3848(20)30389-3"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902\u20137. https:\/\/doi.org\/10.1182\/blood-2007-10-116327; PMID:\u00a018216292.","DOI":"10.1182\/blood-2007-10-116327"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients \u2013 risk scores and recent randomised controlled trials. Thromb Haemost 2012;108:1042\u20138. https:\/\/doi.org\/10.1160\/TH12-04-0241; PMID:\u00a022836491.","DOI":"10.1160\/TH12-04-0241"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study. Oncologist 2017;22:1222\u201331. https:\/\/doi.org\/10.1634\/theoncologist.2016-0414; PMID:\u00a028550032.","DOI":"10.1634\/theoncologist.2016-0414"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Spyropoulos AC, Eldredge JB, Anand LN, et al. External validation of a venous thromboembolic risk score for cancer outpatients with solid tumors: the COMPASS-CAT venous thromboembolism risk assessment model. Oncologist 2020;25:e1083\u201390. https:\/\/doi.org\/10.1634\/theoncologist.2019-0482; PMID:\u00a032017293.","DOI":"10.1634\/theoncologist.2019-0482"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz AJ, Souto JC, Lecumberri R, et al. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning. Thromb Res 2023;228:181\u20138. https:\/\/doi.org\/10.1016\/j.thromres.2023.06.015; PMID:\u00a037348318.","DOI":"10.1016\/j.thromres.2023.06.015"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Lanting VR, Takada T, Bosch FTM, et al. Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model. Thromb Haemost 2025;125:589\u201396. https:\/\/doi.org\/10.1055\/a-2418-3960; PMID:\u00a039299270.","DOI":"10.1055\/a-2418-3960"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Fernandes CJ, Calderaro D, Piloto B, et al. Extended anticoagulation after venous thromboembolism: should it be done? Ther Adv Respir Dis 2019;13:1753466619878556. https:\/\/doi.org\/10.1177\/1753466619878556; PMID:\u00a031558116.","DOI":"10.1177\/1753466619878556"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kuan YKI, Kok YJ, Liu NSH, et al. Artificial intelligence in clinical thrombosis and hemostasis: a review. Res Pract Thromb Haemost 2025;9:102984. https:\/\/doi.org\/10.1016\/j.rpth.2025.102984; PMID:\u00a040837028.","DOI":"10.1016\/j.rpth.2025.102984"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Englisch C, Vladic N, Ay C. Bleeding risk in patients with cancer. Hamostaseologie 2025;45:188\u2013203. https:\/\/doi.org\/10.1055\/a-2347-6507; PMID:\u00a039227022.","DOI":"10.1055\/a-2347-6507"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Frere C, Font C, Esposito F, et al. Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. Support Care Cancer 2022;30:2919\u201331. https:\/\/doi.org\/10.1007\/s00520-021-06598-8; PMID:\u00a034617159.","DOI":"10.1007\/s00520-021-06598-8"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Zakai NA, Walker RF, MacLehose RF, et al. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism. J Thromb Haemost 2018;16:2403\u201312. https:\/\/doi.org\/10.1111\/jth.14303; PMID:\u00a030240508.","DOI":"10.1111\/jth.14303"},{"key":"ref29","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244; PMID:\u00a036017568."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3069a. https:\/\/doi.org\/10.1093\/eurheartj\/ehu283; PMID:\u00a025173341.","DOI":"10.1093\/eurheartj\/ehu243"},{"key":"ref31","unstructured":"Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 2015;33:654\u20136. https:\/\/doi.org\/10.1200\/JCO.2014.59.7351; PMID:\u00a025605844."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146\u201353. https:\/\/doi.org\/10.1056\/NEJMoa025313; PMID:\u00a012853587.","DOI":"10.1056\/NEJMoa025313"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729\u201335. https:\/\/doi.org\/10.1001\/archinte.162.15.1729; PMID:\u00a012153376.","DOI":"10.1001\/archinte.162.15.1729"},{"key":"ref34","unstructured":"Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1711948; PMID:\u00a029231094."},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382:1599\u2013607. https:\/\/doi.org\/10.1056\/NEJMoa1915103; PMID:\u00a032223112.","DOI":"10.1056\/NEJMoa1915103"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:2017\u201323. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034; PMID:\u00a029746227.","DOI":"10.1200\/JCO.2018.78.8034"},{"key":"ref37","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020;18:411\u201321. https:\/\/doi.org\/10.1111\/jth.14662; PMID:\u00a031630479."},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Giustozzi M, Agnelli G, Del Toro-Cervera J, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020;120:1128\u201336. https:\/\/doi.org\/10.1055\/s-0040-1712098; PMID:\u00a032365386.","DOI":"10.1055\/s-0040-1712098"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Becattini C, Bauersachs R, Maraziti G, et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica 2022;107:1567\u201376. https:\/\/doi.org\/10.3324\/haematol.2021.279072; PMID:\u00a034382385.","DOI":"10.3324\/haematol.2021.279072"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Riaz IB, Fuentes H, Deng Y, et al. Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis. JAMA Netw Open 2023;6:e2325283. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.25283; PMID:\u00a037486628.","DOI":"10.1001\/jamanetworkopen.2023.25283"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Sueta D, Yamashita Y, Morimoto T, et al. Edoxaban, Rivaroxaban, or apixaban for cancer-associated venous thromboembolism in the real world: insights from the COMMAND VTE Registry-2. Thromb Haemost 2024;124:1013\u201323. https:\/\/doi.org\/10.1055\/a-2316-5269; PMID:\u00a038684190.","DOI":"10.1055\/a-2316-5269"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Cohen AT, Wallenhorst C, Rivera M, et al. Comparison of clinical outcomes in patients with active cancer receiving rivaroxaban or low-molecular-weight heparin: the OSCAR-UK study. Thromb Haemost 2025;125:265\u201377. https:\/\/doi.org\/10.1055\/a-2259-0662; PMID:\u00a038301711.","DOI":"10.1055\/a-2259-0662"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Yang J, He Z, Li M, et al. Risk of intracranial hemorrhage with direct oral anticoagulation versus low molecular weight heparin in the treatment of brain tumor-associated venous thromboembolism: a meta-analysis. J Stroke Cerebrovasc Dis 2023;32:107243. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2023.107243; PMID:\u00a037413715.","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107243"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Iyengar V, Agrawal S, Chiasakul T, et al. Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review. J Thromb Haemost 2024;22:423\u20139. https:\/\/doi.org\/10.1016\/j.jtha.2023.10.011; PMID:\u00a037866517.","DOI":"10.1016\/j.jtha.2023.10.011"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Goulart TO, Wang C, Fuse K, et al. Intracranial hemorrhage with direct oral anticoagulants vs low-molecular-weight heparin in brain tumors: a review and meta-analysis. Neurology 2025;105:e214140. https:\/\/doi.org\/10.1212\/WNL.0000000000214140; PMID:\u00a040953341.","DOI":"10.1212\/WNL.0000000000214140"},{"key":"ref46","unstructured":"Bueno H, Deaton C, Farrero M, et al. 2025 ESC clinical consensus statement on mental health and cardiovascular disease: developed under the auspices of the ESC Clinical Practice Guidelines Committee. Eur Heart J 2025;46:4156\u2013225. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf191; PMID:\u00a040878270."},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Arteaga AJM, Font C, Rojas Hernandez CM. Quality of life in oncological patients with venous thromboembolic disease. Res Pract Thromb Haemost 2024;8:102510. https:\/\/doi.org\/10.1016\/j.rpth.2024.102510; PMID:\u00a039188888.","DOI":"10.1016\/j.rpth.2024.102510"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Cohen AT, Maraveyas A, Beyer-Westendorf J, et al. COSIMO \u2013 patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. Thromb J 2018;16:21. https:\/\/doi.org\/10.1186\/s12959-018-0176-2; PMID:\u00a030186045.","DOI":"10.1186\/s12959-018-0176-2"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Di Nisio M, van Es N, Carrier M, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost 2019;17:1866\u201374. https:\/\/doi.org\/10.1111\/jth.14561; PMID:\u00a031271705.","DOI":"10.1111\/jth.14561"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Cohen AT, Creeper KJ, Alikhan R, et al. Early time courses of recurrent venous thromboembolism and bleeding during apixaban or dalteparin therapy for patients with cancer. Thromb Haemost 2024;124:676\u201383. https:\/\/doi.org\/10.1055\/s-0043-1778642; PMID:\u00a038196077.","DOI":"10.1055\/s-0043-1778642"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol 2023;34:452\u201367. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.014; PMID:\u00a036638869.","DOI":"10.1016\/j.annonc.2022.12.014"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study. J Thromb Haemost 2015;13:1028\u201335. https:\/\/doi.org\/10.1111\/jth.12923; PMID:\u00a025827941.","DOI":"10.1111\/jth.12923"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Marshall A, Levine M, Hill C, et al. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). J Thromb Haemost 2020;18:905\u201315. https:\/\/doi.org\/10.1111\/jth.14752; PMID:\u00a031995662.","DOI":"10.1111\/jth.14752"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Yamashita Y, Morimoto T, Muraoka N, et al. Rivaroxaban for 18 months versus 6 months in patients with cancer and acute low-risk pulmonary embolism: an open-label, multicenter, randomized clinical trial (ONCO PE trial). Circulation 2025;151:589\u2013600. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072758; PMID:\u00a039556015.","DOI":"10.1161\/CIRCULATIONAHA.125.075703"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Cohen AT, Dhamane AD, Liu X, et al. Effectiveness and safety of extended treatment apixaban versus low-molecular-weight heparin in cancer-associated venous thromboembolism. J Natl Compr Canc Netw 2024;22:397\u2013403. https:\/\/doi.org\/10.6004\/jnccn.2024.7016; PMID:\u00a039151451.","DOI":"10.6004\/jnccn.2024.7016"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Yamashita Y, Morimoto T, Muraoka N, et al. Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis (ONCO DVT study): an open-label, multicenter, randomized clinical trial. Circulation 2023;148:1665\u201376. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066360; PMID:\u00a037638968.","DOI":"10.1161\/CIRCULATIONAHA.123.066360"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Chatani R, Yamashita Y, Morimoto T, et al. Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study. Eur Heart J Cardiovasc Pharmacother 2024;10:422\u201331. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae028; PMID:\u00a038650055.","DOI":"10.1093\/ehjcvp\/pvae028"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Vlazny DT, McBane RD, Casanegra AI, et al. Evaluation of extended direct oral anticoagulant dosing strategies in patients with and without cancer from a prospective observational registry. Res Pract Thromb Haemost 2025;9:102878. https:\/\/doi.org\/10.1016\/j.rpth.2025.102878; PMID:\u00a040519878.","DOI":"10.1016\/j.rpth.2025.102878"},{"key":"ref59","unstructured":"Couturaud F, Schmidt J, Sanchez O, et al. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet 2025;405:725\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(24)02842-3; PMID:\u00a040023651."},{"key":"ref60","unstructured":"McBane RD 2nd, Loprinzi CL, Zemla T, et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial. J Thromb Haemost 2024;22:1704\u201314. https:\/\/doi.org\/10.1016\/j.jtha.2024.03.011; PMID:\u00a038537780."},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Mah\u00e9 I, Carrier M, Mayeur D, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med 2025;392:1363\u201373. https:\/\/doi.org\/10.1056\/NEJMoa2416112; PMID:\u00a040162636.","DOI":"10.1056\/NEJMoa2416112"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Robinson R, Spectre G, Lishner M, et al. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies. J Thromb Thrombolysis 2023;55:729\u201336. https:\/\/doi.org\/10.1007\/s11239-023-02791-0; PMID:\u00a036943661.","DOI":"10.1007\/s11239-023-02791-0"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Lee A, Oley F Jr, Lo M, et al. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors. Thromb Res 2021;208:148\u201355. https:\/\/doi.org\/10.1016\/j.thromres.2021.10.023; PMID:\u00a034798446.","DOI":"10.1016\/j.thromres.2021.10.023"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Carney BJ, Uhlmann EJ, Puligandla M, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost 2019;17:72\u20136. https:\/\/doi.org\/10.1111\/jth.14336; PMID:\u00a030450803.","DOI":"10.1111\/jth.14336"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Mah\u00e9 I, Fr\u00e8re C, Pernod G, et al. Management of venous thromboembolic disease in patients with malignant brain tumours. Arch Cardiovasc Dis 2024;117:60\u201371. https:\/\/doi.org\/10.1016\/j.acvd.2023.11.004; PMID:\u00a038087664.","DOI":"10.1016\/j.acvd.2023.11.004"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Sabatino J, De Rosa S, Polimeni A, et al. Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis. JACC CardioOncol 2020;2:428\u201340. https:\/\/doi.org\/10.1016\/j.jaccao.2020.06.001; PMID:\u00a034396250.","DOI":"10.1016\/j.jaccao.2020.06.001"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Ullah F, Song J, Rojas Hernandez CM, et al. Safety and effectiveness of direct oral anticoagulants for the treatment of gastrointestinal cancer-associated venous thromboembolism. Oncologist 2023;28:e1005\u201316. https:\/\/doi.org\/10.1093\/oncolo\/oyad148; PMID:\u00a037310796.","DOI":"10.1093\/oncolo\/oyad148"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Beavers CJ, Rodgers JE, Bagnola AJ, et al. Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation 2022;145:e811\u201338. https:\/\/doi.org\/10.1161\/CIR.0000000000001056; PMID:\u00a035249373.","DOI":"10.1161\/CIR.0000000000001056"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Nowinski K, Chaireti R. Discrepancies in recommendations on pharmacokinetic drug interactions for anticancer medications and direct oral anticoagulants (DOAC): a comparative analysis of different clinical decision support systems and sources. Pharmaceuticals (Basel) 2025;18:1044. https:\/\/doi.org\/10.3390\/ph18071044; PMID:\u00a040732331.","DOI":"10.3390\/ph18071044"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Verso M, Munoz A, Bauersachs R, et al. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. Eur J Cancer 2021;148:371\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.026; PMID:\u00a033780665.","DOI":"10.1016\/j.ejca.2021.02.026"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Patel SH, George TL, Wang TF, et al. Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. Cancer 2021;127:938\u201345. https:\/\/doi.org\/10.1002\/cncr.33337; PMID:\u00a033216354.","DOI":"10.1002\/cncr.33337"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Falanga A, Leader A, Ambaglio C, et al. EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. Hemasphere 2022;6:e750. https:\/\/doi.org\/10.1097\/HS9.0000000000000750; PMID:\u00a035924068.","DOI":"10.1097\/HS9.0000000000000750"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16:1246\u20139. https:\/\/doi.org\/10.1111\/jth.14015; PMID:\u00a029737593.","DOI":"10.1111\/jth.14015"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Vedovati MC, Giustozzi M, Munoz A, et al. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism. Eur J Intern Med 2023;112:29\u201336. https:\/\/doi.org\/10.1016\/j.ejim.2023.02.003; PMID:\u00a036774305.","DOI":"10.1016\/j.ejim.2023.02.003"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Hussaini P, Larsen TL, Ghanima W, Dahm AEA. Risk factors for bleeding in cancer patients treated with conventional dose followed by low-dose apixaban for venous thromboembolism. Thromb Haemost 2024;124:351\u201362. https:\/\/doi.org\/10.1055\/a-2188-8773; PMID:\u00a037816388.","DOI":"10.1055\/a-2188-8773"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz Mart\u00edn AJ, Lecumberri R, Souto JC, et al. Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing. Clin Transl Oncol 2025;27:1816\u201325. https:\/\/doi.org\/10.1007\/s12094-024-03586-2; PMID:\u00a039276289.","DOI":"10.1007\/s12094-024-03586-2"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Farmakis IT, Barco S, Mavromanoli AC, et al. Performance status and long-term outcomes in cancer-associated pulmonary embolism: insights from the Hokusai-VTE cancer study. JACC CardioOncol 2022;4:507\u201318. https:\/\/doi.org\/10.1016\/j.jaccao.2022.07.008; PMID:\u00a036444229.","DOI":"10.1016\/j.jaccao.2022.07.008"},{"key":"ref78","unstructured":"Goedegebuur J, Abbel D, Accassat S, et al. Towards optimal use of antithrombotic therapy of people with cancer at the end of life: a research protocol for the development and implementation of the SERENITY shared decision support tool. Thromb Res 2023;228:54\u201360. https:\/\/doi.org\/10.1016\/j.thromres.2023.05.008; PMID:\u00a037276718."},{"key":"ref79","unstructured":"Praz F, Borger MA, Lanz J, et al. ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2025;2025:ehaf194."},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Bejjani A, Khairani CD, Assi A, et al. When direct oral anticoagulants should not be standard treatment: JACC state-of-the-art review. J Am Coll Cardiol 2024;83:444\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.038; PMID:\u00a038233019.","DOI":"10.1016\/j.jacc.2023.10.038"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Kempers EK, Visser C, Geijteman ECT, et al. Discontinuation of anticoagulants and occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease. Thromb Haemost 2025. https:\/\/doi.org\/10.1055\/a-2524-5334; PMID:\u00a039855271.","DOI":"10.1055\/a-2524-5334"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Visser C, Kempers EK, Goedgebuur J, et al. Quality of vitamin K antagonist treatment during the last year of life. Hemasphere 2025;9:e70135. https:\/\/doi.org\/10.1002\/hem3.70135; PMID:\u00a040390869.","DOI":"10.1002\/hem3.70173"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Martens ESL, Becker D, Abele C, et al. Understanding European patterns of deprescribing antithrombotic medication during end-of-life care in patients with cancer. Thromb Res 2025;245:109205. https:\/\/doi.org\/10.1016\/j.thromres.2024.109205; PMID:\u00a039667100.","DOI":"10.1016\/j.thromres.2024.109205"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Baddeley E, Font C, Mah\u00e9 I, et al. \u201cWho am I to say that I\u2019m not going to take it\u201d: patient perspectives on decisions about antithrombotic therapy in the context of advanced cancer. Thromb Res 2025;253:109399. https:\/\/doi.org\/10.1016\/j.thromres.2025.109399; PMID:\u00a040651261.","DOI":"10.1016\/j.thromres.2025.109399"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Aldridge SJ, Akbari A, Edwards A, et al. Anti-thrombotic therapy in patients with cancer at the end of life: a cohort study using population-linked routinely collected data. Br J Haematol 2025;207:2080\u201390. https:\/\/doi.org\/10.1111\/bjh.70032; PMID:\u00a040890090.","DOI":"10.1111\/bjh.70032"}],"container-title":["European Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.46","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:53:31Z","timestamp":1773158011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":86,"URL":"https:\/\/doi.org\/10.15420\/ecr.2025.46","relation":{},"ISSN":["1758-3756","1758-3764"],"issn-type":[{"value":"1758-3756","type":"print"},{"value":"1758-3764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"article-number":"e14"}}